BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11248325)

  • 1. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes.
    Wimazal F; Sperr WR; Kundi M; Meidlinger P; Fonatsch C; Jordan JH; Thalhammer-Scherrer R; Schwarzinger I; Geissler K; Lechner K; Valent P
    Leuk Res; 2001 Apr; 25(4):287-94. PubMed ID: 11248325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).
    Germing U; Hildebrandt B; Pfeilstöcker M; Nösslinger T; Valent P; Fonatsch C; Lübbert M; Haase D; Steidl C; Krieger O; Stauder R; Giagounidis AA; Strupp C; Kündgen A; Mueller T; Haas R; Gattermann N; Aul C
    Leukemia; 2005 Dec; 19(12):2223-31. PubMed ID: 16193087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.
    Musto P; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G; Modoni S; Parlatore L; Valvano MR; Carotenuto M
    Br J Haematol; 1995 May; 90(1):125-30. PubMed ID: 7786774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum deoxythymidine kinase in myelodysplastic syndromes.
    Aul C; Gattermann N; Germing U; Winkelmann M; Heyll A; Runde V; Schneider W
    Cancer; 1994 Jan; 73(2):322-7. PubMed ID: 8293395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
    Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
    Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems.
    Sperr WR; Wimazal F; Kundi M; Fonatsch C; Thalhammer-Scherrer R; Schernthaner GH; Schwarzinger I; Haas OA; Geissler K; Lechner K; Valent P
    Ann Hematol; 2001 May; 80(5):272-7. PubMed ID: 11446729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes.
    Wimazal F; Sperr WR; Kundi M; Vales A; Fonatsch C; Thalhammer-Scherrer R; Schwarzinger I; Valent P
    Ann Oncol; 2008 May; 19(5):970-6. PubMed ID: 18272915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic significance of serial determinations of lactate dehydrogenase in follow-up for patients with myelodysplastic syndrome].
    Zhang YQ; Dai HB; Wang JH; Li XY; Dai SM; Yao DD; Ma LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):85-9. PubMed ID: 21362228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment in primary myelodysplastic syndromes: validation of the Düsseldorf score.
    Aul C; Gattermann N; Germing U; Runde V; Heyll A; Schneider W
    Leukemia; 1994 Nov; 8(11):1906-13. PubMed ID: 7967735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.
    Varma N; Varma S
    Indian J Pathol Microbiol; 2008; 51(1):97-101. PubMed ID: 18417875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
    Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
    Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlation of laboratory indexes with prognosis in patients with myelodysplastic syndrome].
    Li WW; Li Y; Wang XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):116-9. PubMed ID: 22391179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the International Prognostic Scoring System for myelodysplastic syndromes.
    Maes B; Meeus P; Michaux L; Bijnens L; Boogaerts M; Hagemeijer A; De Wolf-Peeters C; Verhoef G
    Ann Oncol; 1999 Jul; 10(7):825-9. PubMed ID: 10470430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The International Prognostic Scoring System for primary myelodysplastic syndrome].
    Sisková M; Dohnalová A; Neuwirtová R; Pĕnicková J; Karban J; Cmunt E
    Sb Lek; 2002; 103(3):333-8. PubMed ID: 12688177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia.
    Bacher U; Haferlach T; Kern W; Haferlach C; Schnittger S
    Haematologica; 2007 Jun; 92(6):744-52. PubMed ID: 17550846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis.
    Raymakers R; Preijers F; Boezeman J; Rutten E; De Witte T
    Leuk Lymphoma; 1994 Jun; 14(1-2):111-20. PubMed ID: 7920217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.
    Bernstein SH; Brunetto VL; Davey FR; Wurster-Hill D; Mayer RJ; Stone RM; Schiffer CA; Bloomfield CD
    J Clin Oncol; 1996 Sep; 14(9):2486-94. PubMed ID: 8823327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment.
    Moon JH; Kim SN; Kang BW; Chae YS; Kim JG; Baek JH; Park JH; Song MK; Chung JS; Won JH; Lee SM; Joo YD; Kim YK; Kim HJ; Jo DY; Sohn SK
    Ann Hematol; 2010 Jul; 89(7):681-9. PubMed ID: 20237926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.